Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy.
Munir, T Rawstron, A Brock, K Vicente, S Yates, F Bishop, R Fegan, C Macdonald, D Mccaig, A Schuh, A
Munir, T
Rawstron, A
Brock, K
Vicente, S
Yates, F
Bishop, R
Fegan, C
Macdonald, D
Mccaig, A
Schuh, A
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. 2018, 181: 34-35 BR J Haematol